<DOC>
	<DOCNO>NCT00709540</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multiple-dose , dose-escalating study evaluate safety , tolerability , pharmacokinetics pharmacodynamics ACE-011 healthy postmenopausal woman .</brief_summary>
	<brief_title>A Safety , Tolerability Pharmacodynamics Study ACE-011 ( ActRIIA-IgG1 ) Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>1 . Subject postmenopausal woman , 4585 year old ( inclusive ) . 2 . Subject 12 month spontaneous amenorrhea , OR 6 month spontaneous amenorrhea serum follicle stimulate hormone ( FSH ) level &gt; 40 IU/L OR 6 week postsurgical bilateral oophorectomy without hysterectomy . 3 . Subject take least 500 mg calcium supplement 400 IU vitamin D daily follow regimen least 4 week prior first dose study drug administration . 4 . Subject body mass index ( BMI ) â‰¥ 18.5 &lt; 30 . 5 . Subject must give write informed consent . If require local law , candidate must also authorize release use protect health information ( PHI ) . 1 . Subject history clinically significant major disease ( determined Investigator ) . 2 . Subject history hyperparathyroidism , hypoparathyroidism , hypocalcemia , rheumatoid arthritis , myeloproliferative disorder , gout , Paget 's disease bone , osteomalacia . 3 . Subject long bone fracture within past 6 month prior enrollment , osteoporosisrelated fracture within previous 2 year . 4 . Subject history opportunistic infection , serious local systemic infection within 3 month prior screen . 5 . Subject history severe allergic anaphylactic reaction . 6 . Subject major surgery within previous 3 month . 7 . Subject history drug alcohol abuse , test positive drug alcohol screen screen Day 1 prior dose . 8 . Subject consume alcohol within 72 hour prior dose . 9 . Subject give blood donation ( one unit ) within 1 month prior dose , plan give blood donation course study . 10 . Subject take follow bone active medication : Teriparatide time lifetime . Fluoride therapy 3 month previous 2 year . Estrogen , androgen , anabolic steroid , corticosteroid ( exclude inhale , topical local injection joint pain ) , calcitonin , bone active drug ( e.g . selective estrogen receptor modulators ) within 4 month prior screen . Bisphosphonates : If treat 6 month time lifetime . If treat 3 6 month within 2 year screen . If treat less 3 month within 6 month screen . 11 . Subjects chronic stable disease include migraine , hypertension , hyperthyroid disorder , hypothyroid disorder , gastroesophageal reflux disease , mild depression/anxiety exclude unless investigator safety compliance concern study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>